ckd glp 1 GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists Kidney and Cardiovascular Outcomes Among

Curr Nutr Rep 12 , 6682 (2023)

Cotadutide (MEDI0382) is the most extensively developed dual GLP-1/glucagon receptor agonist, showing significant improvements in glucose control, BW (likely mediated by reduced energy intake rather than increased energy expenditure), hepatic fat, and albuminuria in a small RCT on patients with T2D and overweight or obesity 45,46

Within the estrogen detoxification cascade, GSTM1 has been the more extensively studied of the two for catechol estrogen quinone conjugation

- Alimentation quilibre :Associer la L-Carnitine une alimentation varie, riche en protines, fruits et lgumes, et adapte son niveau dactivit

Typically administered as weekly subcutaneous injections, GLP-1 agonists can be injected into areas with fat just beneath the skin, such as the abdomen or back of the arms

Importantly, no significant side effects were recorded, providing proof of concept for GLP-1 therapy in subjects with T2D